WO2004042389A3 - Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d) - Google Patents

Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d) Download PDF

Info

Publication number
WO2004042389A3
WO2004042389A3 PCT/EP2003/011877 EP0311877W WO2004042389A3 WO 2004042389 A3 WO2004042389 A3 WO 2004042389A3 EP 0311877 W EP0311877 W EP 0311877W WO 2004042389 A3 WO2004042389 A3 WO 2004042389A3
Authority
WO
WIPO (PCT)
Prior art keywords
pde4d
diseases
therapeutics
diagnostics
disorders
Prior art date
Application number
PCT/EP2003/011877
Other languages
French (fr)
Other versions
WO2004042389A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Priority to AU2003301894A priority Critical patent/AU2003301894A1/en
Publication of WO2004042389A2 publication Critical patent/WO2004042389A2/en
Publication of WO2004042389A3 publication Critical patent/WO2004042389A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides a human PDE4D which is associated with the disorders of the peripheral and central nervous system, cardiovascular diseases, hematological diseases, respiratory diseases and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the peripheral and central nervous system, cardiovascular diseases, hematological diseases, respiratory diseases and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of PDE4D as well as pharmaceutical compositions comprising such compounds.
PCT/EP2003/011877 2002-11-08 2003-10-25 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d) WO2004042389A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003301894A AU2003301894A1 (en) 2002-11-08 2003-10-25 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02024993 2002-11-08
EP02024993.4 2002-11-08

Publications (2)

Publication Number Publication Date
WO2004042389A2 WO2004042389A2 (en) 2004-05-21
WO2004042389A3 true WO2004042389A3 (en) 2004-08-05

Family

ID=32309317

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/011877 WO2004042389A2 (en) 2002-11-08 2003-10-25 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d)

Country Status (2)

Country Link
AU (1) AU2003301894A1 (en)
WO (1) WO2004042389A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2004090157A1 (en) * 2003-04-10 2004-10-21 F. Hoffmann-La Roche Ag The use of pde4d in the screening for medicaments against atherosclerosis
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
CA2591924A1 (en) * 2004-12-16 2006-07-06 The Trustees Of Columbia University In The City Of New York Phosphodiesterase 4d in the ryanodine receptor complex protects against heart failure
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
BRPI1007704A2 (en) * 2009-05-12 2019-12-03 Koninl Philips Electronics Nv phosphodiesterase 4d7 (pde4d7), for use as a marker for hormone-sensitive malignant prostate cancer; composition or method of data acquisition or immunoassay to diagnose, detect, monitor or predict hormone-sensitive malignant prostate cancer or to diagnose, detect, monitor or predict progression to hormone-sensitive malignant prostate cancer; use of pde4d7; immunoassay to discriminate between a benign prostate tumor and a hormone-sensitive malignant prostate cancer; method for identifying an individual for eligibility for hormone-sensitive malignant prostate cancer therapy; immunoassay to classify an individual or section of individuals with a hormone-sensitive malignant prostate cancer disease; inhibitory pharmaceutical composition for the treatment or prevention of hormone sensitive malignant prostate cancer; stimulatory pharmaceutical composition; and; use of a pde4d7 protein-specific antibody and / or a pde4d7 protein-specific antibody variant
US9828604B2 (en) 2009-05-12 2017-11-28 Koninklijke Philips N.V. Phosphodiesterase 9A as prostate cancer marker
JP6148007B2 (en) * 2009-05-12 2017-06-14 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． Phosphodiesterase 4D7 as a prostate cancer marker

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040714A2 (en) * 1998-12-30 2000-07-13 Oligos Etc. Inc. Therapeutic phosphodiesterase inhibitors
EP1040829A2 (en) * 1998-12-30 2000-10-04 Pfizer Inc. Prokinetic agents for treating gastric hypomotility and related disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040714A2 (en) * 1998-12-30 2000-07-13 Oligos Etc. Inc. Therapeutic phosphodiesterase inhibitors
EP1040829A2 (en) * 1998-12-30 2000-10-04 Pfizer Inc. Prokinetic agents for treating gastric hypomotility and related disorders

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
GIEMBYCZ M: "PDE4D-deficient mice knock the breath out of asthma", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, vol. 21, no. 8, 1 August 2000 (2000-08-01), pages 291 - 292, XP004215216, ISSN: 0165-6147 *
HANSEN G ET AL: "Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 6 JUN 2000, vol. 97, no. 12, 6 June 2000 (2000-06-06), pages 6751 - 6756, XP002278928, ISSN: 0027-8424 *
KOSTIC M M ET AL: "Altered expression of PDE1 and PDE4 cyclic nucleotide phosphodiesterase isoforms in 7-oxo-prostacyclin-preconditioned rat heart.", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY. NOV 1997, vol. 29, no. 11, November 1997 (1997-11-01), pages 3135 - 3146, XP002278927, ISSN: 0022-2828 *
LANDELLS L J ET AL: "IDENTIFICATION AND QUANTIFICATION OF PHOSPHODIESTERASE 4 SUBTYPES IN CD4 AND CD18 LYMPHOCYTES FROM HEALTHY AND ASTHMATIC SUBJECTS", BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 133, no. 5, July 2001 (2001-07-01), pages 722 - 729, XP001037833, ISSN: 0007-1188 *
LUGNIER C ET AL: "Characterization of cyclic nucleotide phosphodiesterase isoforms associated to isolated cardiac nuclei.", BIOCHIMICA ET BIOPHYSICA ACTA. 16 NOV 1999, vol. 1472, no. 3, 16 November 1999 (1999-11-16), pages 431 - 446, XP002278929, ISSN: 0006-3002 *
MULLER T ET AL: "Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, vol. 17, no. 8, 1 August 1996 (1996-08-01), pages 294 - 298, XP004034578, ISSN: 0165-6147 *
PEREZ-TORRES S ET AL: "Cellular expression of cAMP phosphodiesterase PDE4A, PDE4B and PDE4D mRNAs in Alzheimer's disease brains", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 1, 2001, & 31ST ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE; SAN DIEGO, CALIFORNIA, USA; NOVEMBER 10-15, 2001, pages 1134, XP002270742, ISSN: 0190-5295 *
PEREZ-TORRES S ET AL: "Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and (3H)rolipram binding autoradiography comparison with monkey and rat brain", JOURNAL OF CHEMICAL NEUROANATOMY, CHICHESTER, GB, vol. 20, no. 3-4, December 2000 (2000-12-01), pages 349 - 374, XP002275597, ISSN: 0891-0618 *
TAKAHASHI KOKI ET AL: "Enhanced activities and gene expression of phosphodiesterase types 3 and 4 in pressure-induced congestive heart failure.", HEART AND VESSELS. SEP 2002, vol. 16, no. 6, September 2002 (2002-09-01), pages 249 - 256, XP002278931, ISSN: 0910-8327 *
THOMAS N J ET AL: "Chronic type IV phosphodiesterase inhibition protects glomerular filtration rate and renal and mesenteric blood flow in a zymosan-induced model of multiple organ dysfunction syndrome treated with norepinephrine.", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. JAN 2001, vol. 296, no. 1, January 2001 (2001-01-01), pages 168 - 174, XP002278930, ISSN: 0022-3565 *

Also Published As

Publication number Publication date
AU2003301894A1 (en) 2004-06-07
AU2003301894A8 (en) 2004-06-07
WO2004042389A2 (en) 2004-05-21

Similar Documents

Publication Publication Date Title
WO2004042389A3 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d)
WO2003093816A3 (en) Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr)
WO2005040828A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
WO2004042402A3 (en) Diagnostics and therapeutics for diseases associated with human mas-related gene x1 (mrgx1)
WO2003065044A3 (en) Diagnostics and therapeutics for diseases associated with gpr72
WO2004071378A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a)
WO2004038405A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43)
WO2004042390A3 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4b (pde4b)
WO2003095967A3 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 9(ccr9)
WO2004038421A3 (en) Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 41 (gpr41)
WO2004071394A3 (en) Diagnostics and therapeutics for diseases associated with hm74
WO2003100433A3 (en) Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 3 (avpr3)
WO2003100435A3 (en) Diagnostics and therapeutic use of neuromedin u receptor 2 (nmu2)
WO2003096020A3 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 8 (ccr8)
WO2004042077A3 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 8b (pde8b)
WO2003083135A3 (en) Diagnostics and therapeutics for diseases associated with neuropeptide ff receptor 2 (npff2)
WO2004042076A3 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4a (pde4a)
WO2004050903A3 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4c (pde4c)
WO2003066077A3 (en) Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1)
WO2003100434A3 (en) Diagnostic and therapeutic use of the arginine vasopressin receptor 2 (avpr2)
WO2004038406A3 (en) Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 42 (gpr42)
WO2004072651A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine 1f receptor (5-ht1f)
WO2004042405A3 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 3 (gpr3)
WO2003081257A3 (en) Diagnostics and therapeutics for diseases associated with neuropeptide ff receptor 1 (npff1)
WO2004071395A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor ox1r (ox1r)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP